3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
68
Gastrointestinal
23
Thoracic
11
CNS
9
Tumor-Agnostic
8
Gynecologic
7
Sarcoma
3
Head & Neck
3
Other solid neoplasm
2
Genitourinary
2
Dermatologic
1
Conditions
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Anus Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
161
Nivolumab
133
Ipilimumab
78
Cyclophosphamide
47
Specimen Handling
43
Magnetic Resonance Spectroscopy
39
cemiplimab
35
Biopsy
31
fludarabine
29
trametinib
24
relatlimab
24
binimetinib
23
Interleukin-2
22
fludarabine phosphate
21
dabrafenib
20
atezolizumab
19
Radiotherapy
19
Opdualag
19
aldesleukin
18
Radiosurgery
18
CTLA-4 Antigen
18
encorafenib
17
Blood Specimen Collection
17
avelumab
14
Immunoglobulin G
14
Disulfides
13
lifileucel
11
lenvatinib
11
Bevacizumab
11
Paclitaxel
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
trastuzumab deruxtecan
×
Dermatologic
×
1 year
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled